Market revenue in 2021 | USD 17.4 million |
Market revenue in 2030 | USD 33.9 million |
Growth rate | 7.7% (CAGR from 2021 to 2030) |
Largest segment | Biomarker assay development & validation |
Fastest growing segment | Flow cytometry |
Historical data | 2018 - 2020 |
Base year | 2021 |
Forecast period | 2022 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Biomarker Assay Development & Validation, Flow cytometry, Others( Biomarker immunoassays, Biomarker Assessment) |
Key market players worldwide | Eurofins Scientific SE, SGS AG, Charles River Laboratories International Inc, Labcorp Drug Development, Thermo Fisher Scientific Inc, Icon PLC, IQVIA Holdings Inc, Syneos Health, Intertek Group PLC, BioAgilytix Labs |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to biomarker testing services market will help companies and investors design strategic landscapes.
Biomarker assay development & validation was the largest segment with a revenue share of 59.77% in 2024. Horizon Databook has segmented the Germany biomarker testing services market based on biomarker assay development & validation, flow cytometry, others( biomarker immunoassays, biomarker assessment) covering the revenue growth of each sub-segment from 2018 to 2030.
The biomarker testing services market in Germany is driven by technological advancements, enhanced clinical team expertise, increased demand for vaccines, biologics & other biopharmaceutical drugs, and low labor costs that support the demand for biomarkers & have increased competitiveness in the global market.
These factors are expected to drive the market over the forecast period. Furthermore, increasing demand for outsourcing services would drive the demand for biomarker testing services. In addition, many large pharmaceutical/biopharmaceutical companies are outsourcing their R&D for drug discovery alliances to develop partnerships which is expected to contribute to the market growth.
These collaborations may include extensive biomarker testing services to support the development & validation of new drug candidates. Such actions are likely to promote market growth in the country.
Horizon Databook provides a detailed overview of country-level data and insights on the Germany biomarker testing services market , including forecasts for subscribers. This country databook contains high-level insights into Germany biomarker testing services market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account